Annual CFI
$144.45 M
+$388.77 M+159.12%
31 December 2023
Summary:
Foghorn Therapeutics annual cash flow from investing activities is currently $144.45 million, with the most recent change of +$388.77 million (+159.12%) on 31 December 2023. During the last 3 years, it has risen by +$253.36 million (+232.63%). FHTX annual CFI is now at all-time high.FHTX Cash From Investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFI
-$61.31 M
-$43.34 M-241.11%
30 September 2024
Summary:
Foghorn Therapeutics quarterly cash flow from investing activities is currently -$61.31 million, with the most recent change of -$43.34 million (-241.11%) on 30 September 2024. Over the past year, it has dropped by -$99.74 million (-259.57%). FHTX quarterly CFI is now -179.54% below its all-time high of $77.09 million, reached on 30 June 2021.FHTX Quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFI
-$14.81 M
-$99.74 M-117.44%
30 September 2024
Summary:
Foghorn Therapeutics TTM cash flow from investing activities is currently -$14.81 million, with the most recent change of -$99.74 million (-117.44%) on 30 September 2024. Over the past year, it has dropped by -$115.37 million (-114.73%). FHTX TTM CFI is now -110.25% below its all-time high of $144.45 million, reached on 31 December 2023.FHTX TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
FHTX Cash From Investing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +159.1% | -259.6% | -114.7% |
| 3 y3 years | +232.6% | -29.6% | +79.9% |
| 5 y5 years | +9473.8% | - | - |
FHTX Cash From Investing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +159.1% | -233.2% | +61.5% | -110.3% | +95.4% |
| 5 y | 5 years | at high | +159.1% | -179.5% | +61.5% | -110.3% | +95.4% |
| alltime | all time | at high | +159.1% | -179.5% | +61.5% | -110.3% | +95.4% |
Foghorn Therapeutics Cash From Investing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$61.31 M(+241.1%) | -$14.81 M(-117.4%) |
| June 2024 | - | -$17.98 M(-166.3%) | $84.93 M(-40.2%) |
| Mar 2024 | - | $27.09 M(-27.5%) | $142.04 M(-1.7%) |
| Dec 2023 | $144.45 M(-159.1%) | $37.38 M(-2.7%) | $144.45 M(+43.6%) |
| Sept 2023 | - | $38.43 M(-1.8%) | $100.56 M(-7.0%) |
| June 2023 | - | $39.13 M(+32.6%) | $108.18 M(-295.2%) |
| Mar 2023 | - | $29.50 M(-553.4%) | -$55.41 M(-77.3%) |
| Dec 2022 | -$244.32 M | -$6.51 M(-114.1%) | -$244.32 M(+7.1%) |
| Sept 2022 | - | $46.05 M(-137.0%) | -$228.14 M(-29.0%) |
| June 2022 | - | -$124.46 M(-21.9%) | -$321.52 M(+168.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2022 | - | -$159.41 M(-1748.0%) | -$119.97 M(-431.7%) |
| Dec 2021 | $36.17 M(-133.2%) | $9.67 M(-120.4%) | $36.17 M(-149.1%) |
| Sept 2021 | - | -$47.33 M(-161.4%) | -$73.72 M(+131.7%) |
| June 2021 | - | $77.09 M(-2464.0%) | -$31.82 M(-71.4%) |
| Mar 2021 | - | -$3.26 M(-96.7%) | -$111.15 M(+2.1%) |
| Dec 2020 | -$108.91 M(>+9900.0%) | -$100.22 M(+1747.4%) | -$108.91 M(+1152.7%) |
| Sept 2020 | - | -$5.42 M(+141.3%) | -$8.69 M(+166.0%) |
| June 2020 | - | -$2.25 M(+120.2%) | -$3.27 M(+220.2%) |
| Mar 2020 | - | -$1.02 M | -$1.02 M |
| Dec 2019 | -$964.00 K(-37.4%) | - | - |
| Dec 2018 | -$1.54 M | - | - |
FAQ
- What is Foghorn Therapeutics annual cash flow from investing activities?
- What is the all time high annual CFI for Foghorn Therapeutics?
- What is Foghorn Therapeutics annual CFI year-on-year change?
- What is Foghorn Therapeutics quarterly cash flow from investing activities?
- What is the all time high quarterly CFI for Foghorn Therapeutics?
- What is Foghorn Therapeutics quarterly CFI year-on-year change?
- What is Foghorn Therapeutics TTM cash flow from investing activities?
- What is the all time high TTM CFI for Foghorn Therapeutics?
- What is Foghorn Therapeutics TTM CFI year-on-year change?
What is Foghorn Therapeutics annual cash flow from investing activities?
The current annual CFI of FHTX is $144.45 M
What is the all time high annual CFI for Foghorn Therapeutics?
Foghorn Therapeutics all-time high annual cash flow from investing activities is $144.45 M
What is Foghorn Therapeutics annual CFI year-on-year change?
Over the past year, FHTX annual cash flow from investing activities has changed by +$388.77 M (+159.12%)
What is Foghorn Therapeutics quarterly cash flow from investing activities?
The current quarterly CFI of FHTX is -$61.31 M
What is the all time high quarterly CFI for Foghorn Therapeutics?
Foghorn Therapeutics all-time high quarterly cash flow from investing activities is $77.09 M
What is Foghorn Therapeutics quarterly CFI year-on-year change?
Over the past year, FHTX quarterly cash flow from investing activities has changed by -$99.74 M (-259.57%)
What is Foghorn Therapeutics TTM cash flow from investing activities?
The current TTM CFI of FHTX is -$14.81 M
What is the all time high TTM CFI for Foghorn Therapeutics?
Foghorn Therapeutics all-time high TTM cash flow from investing activities is $144.45 M
What is Foghorn Therapeutics TTM CFI year-on-year change?
Over the past year, FHTX TTM cash flow from investing activities has changed by -$115.37 M (-114.73%)